Meta‐analysis: vasoactive medications for the management of acute variceal bleeds

Summary Background Vasoactive medications such as vasopressin, somatostatin and their analogues (terlipressin, vapreotide and octreotide) are commonly used for the treatment of acute variceal bleeding. However, the risks and benefits of these interventions are not well understood. Aim To undertake a meta‐analysis of the efficacy of vasoactive medications in patients having acute variceal bleeds. Methods Randomised controlled trials ( RCTs ) of vasopressin, somatostatin and their analogues, administered to patients with acute variceal bleeds were identified based on systematic searches of nine electronic databases and multiple sources of grey literature. Results The search identified 3011 citations, and 30 trials with a total of 3111 patients met eligibility criteria. The use of vasoactive agents was associated with a significantly lower risk of 7‐day mortality ( RR 0.74; 95% CI 0.57–0.95; P = 0.02; I 2 = 0%; moderate quality of evidence), and a significant improvement in haemostasis ( RR 1.21, 95% CI 1.13–1.30; P < 0.001; I 2 = 28%; very low quality of evidence), lower transfusion requirements (pooled mean difference −0.70 units of blood transfused, 95% CI −1.01 to −0.38; P < 0.001; I 2 = 82%; moderate quality of evidence), and a shorter duration of hospitalisation (pooled mean difference −0.71 days; 95% CI −1.23 to −0.19; P = 0.007; I 2 = 0%; low quality of evidence). Studies comparing different vasoactive agents did not show a difference in efficacy, although the quality of evidence was very low. Conclusions The use of vasoactive agents was associated with a significantly lower risk of acute all‐cause mortality and transfusion requirements, and improved control of bleeding and shorter hospital stay. Studies comparing different vasoactive medications failed to demonstrate a difference in efficacy.